vs

Side-by-side financial comparison of California BanCorp \ CA (BCAL) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

California BanCorp \ CA is the larger business by last-quarter revenue ($45.9M vs $35.5M, roughly 1.3× RECURSION PHARMACEUTICALS, INC.). California BanCorp \ CA runs the higher net margin — 35.8% vs -304.2%, a 340.0% gap on every dollar of revenue. On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs 0.8%). California BanCorp \ CA produced more free cash flow last quarter ($56.9M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 44.7%).

Pacific Premier Bancorp, Inc. is an American bank holding company under the Bank Holding Company Act of 1956 headquartered in Irvine, California, US. Its principal business focuses on Pacific Premier Bank, which offers a range of financial services to individuals, businesses, and professionals. The bank operates numerous branches in California, Arizona, Nevada, and Washington.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

BCAL vs RXRX — Head-to-Head

Bigger by revenue
BCAL
BCAL
1.3× larger
BCAL
$45.9M
$35.5M
RXRX
Growing faster (revenue YoY)
RXRX
RXRX
+681.0% gap
RXRX
681.7%
0.8%
BCAL
Higher net margin
BCAL
BCAL
340.0% more per $
BCAL
35.8%
-304.2%
RXRX
More free cash flow
BCAL
BCAL
$104.3M more FCF
BCAL
$56.9M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
44.7%
BCAL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCAL
BCAL
RXRX
RXRX
Revenue
$45.9M
$35.5M
Net Profit
$16.4M
$-108.1M
Gross Margin
59.8%
Operating Margin
48.8%
-304.8%
Net Margin
35.8%
-304.2%
Revenue YoY
0.8%
681.7%
Net Profit YoY
-2.1%
39.6%
EPS (diluted)
$0.50
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCAL
BCAL
RXRX
RXRX
Q4 25
$45.9M
$35.5M
Q3 25
$45.2M
$5.2M
Q2 25
$44.3M
$19.2M
Q1 25
$44.8M
$14.7M
Q4 24
$45.5M
$4.5M
Q3 24
$38.1M
$26.1M
Q2 24
$22.2M
$14.4M
Q1 24
$21.9M
$13.8M
Net Profit
BCAL
BCAL
RXRX
RXRX
Q4 25
$16.4M
$-108.1M
Q3 25
$15.7M
$-162.3M
Q2 25
$14.1M
$-171.9M
Q1 25
$16.9M
$-202.5M
Q4 24
$16.8M
$-178.9M
Q3 24
$-16.5M
$-95.8M
Q2 24
$190.0K
$-97.5M
Q1 24
$4.9M
$-91.4M
Gross Margin
BCAL
BCAL
RXRX
RXRX
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Q1 24
19.1%
Operating Margin
BCAL
BCAL
RXRX
RXRX
Q4 25
48.8%
-304.8%
Q3 25
48.3%
-3327.6%
Q2 25
45.3%
-916.8%
Q1 25
52.8%
-1297.9%
Q4 24
52.2%
-4042.4%
Q3 24
-59.1%
-377.1%
Q2 24
1.3%
-697.4%
Q1 24
33.1%
-698.4%
Net Margin
BCAL
BCAL
RXRX
RXRX
Q4 25
35.8%
-304.2%
Q3 25
34.7%
-3135.3%
Q2 25
31.8%
-894.2%
Q1 25
37.6%
-1373.3%
Q4 24
37.7%
-3935.5%
Q3 24
-43.2%
-367.5%
Q2 24
0.9%
-676.6%
Q1 24
22.5%
-662.4%
EPS (diluted)
BCAL
BCAL
RXRX
RXRX
Q4 25
$0.50
$-0.17
Q3 25
$0.48
$-0.36
Q2 25
$0.43
$-0.41
Q1 25
$0.52
$-0.50
Q4 24
$0.54
$-0.56
Q3 24
$-0.59
$-0.34
Q2 24
$0.01
$-0.40
Q1 24
$0.26
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCAL
BCAL
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$399.9M
$743.3M
Total DebtLower is stronger
$33.8M
$9.6M
Stockholders' EquityBook value
$576.6M
$1.1B
Total Assets
$4.0B
$1.5B
Debt / EquityLower = less leverage
0.06×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCAL
BCAL
RXRX
RXRX
Q4 25
$399.9M
$743.3M
Q3 25
$559.2M
$659.8M
Q2 25
$430.1M
$525.1M
Q1 25
$439.2M
$500.5M
Q4 24
$388.2M
$594.4M
Q3 24
$614.4M
$427.6M
Q2 24
$104.7M
$474.3M
Q1 24
$86.5M
$296.3M
Total Debt
BCAL
BCAL
RXRX
RXRX
Q4 25
$33.8M
$9.6M
Q3 25
$33.4M
$11.9M
Q2 25
$52.9M
$14.2M
Q1 25
$70.3M
$16.4M
Q4 24
$69.7M
$19.0M
Q3 24
$69.1M
$20.5M
Q2 24
$42.9M
$22.9M
Q1 24
$44.9M
Stockholders' Equity
BCAL
BCAL
RXRX
RXRX
Q4 25
$576.6M
$1.1B
Q3 25
$564.7M
$1.0B
Q2 25
$547.6M
$919.1M
Q1 25
$531.4M
$933.9M
Q4 24
$511.8M
$1.0B
Q3 24
$498.1M
$524.6M
Q2 24
$293.2M
$584.4M
Q1 24
$292.5M
$401.2M
Total Assets
BCAL
BCAL
RXRX
RXRX
Q4 25
$4.0B
$1.5B
Q3 25
$4.1B
$1.4B
Q2 25
$4.0B
$1.3B
Q1 25
$4.0B
$1.3B
Q4 24
$4.0B
$1.4B
Q3 24
$4.4B
$726.5M
Q2 24
$2.3B
$775.9M
Q1 24
$2.3B
$557.8M
Debt / Equity
BCAL
BCAL
RXRX
RXRX
Q4 25
0.06×
0.01×
Q3 25
0.06×
0.01×
Q2 25
0.10×
0.02×
Q1 25
0.13×
0.02×
Q4 24
0.14×
0.02×
Q3 24
0.14×
0.04×
Q2 24
0.15×
0.04×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCAL
BCAL
RXRX
RXRX
Operating Cash FlowLast quarter
$57.3M
$-46.1M
Free Cash FlowOCF − Capex
$56.9M
$-47.3M
FCF MarginFCF / Revenue
124.1%
-133.1%
Capex IntensityCapex / Revenue
0.8%
3.5%
Cash ConversionOCF / Net Profit
3.49×
TTM Free Cash FlowTrailing 4 quarters
$93.1M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCAL
BCAL
RXRX
RXRX
Q4 25
$57.3M
$-46.1M
Q3 25
$16.0M
$-117.4M
Q2 25
$13.4M
$-76.4M
Q1 25
$7.0M
$-132.0M
Q4 24
$50.3M
$-115.4M
Q3 24
$18.3M
$-59.2M
Q2 24
$309.0K
$-82.2M
Q1 24
$8.1M
$-102.3M
Free Cash Flow
BCAL
BCAL
RXRX
RXRX
Q4 25
$56.9M
$-47.3M
Q3 25
$15.9M
$-117.6M
Q2 25
$13.4M
$-79.6M
Q1 25
$6.9M
$-133.8M
Q4 24
$49.7M
$-116.7M
Q3 24
$18.1M
$-63.8M
Q2 24
$171.0K
$-83.4M
Q1 24
$8.0M
$-109.0M
FCF Margin
BCAL
BCAL
RXRX
RXRX
Q4 25
124.1%
-133.1%
Q3 25
35.1%
-2272.5%
Q2 25
30.2%
-413.9%
Q1 25
15.3%
-907.4%
Q4 24
109.2%
-2567.7%
Q3 24
47.5%
-244.6%
Q2 24
0.8%
-578.5%
Q1 24
36.4%
-789.9%
Capex Intensity
BCAL
BCAL
RXRX
RXRX
Q4 25
0.8%
3.5%
Q3 25
0.2%
4.7%
Q2 25
0.1%
16.4%
Q1 25
0.2%
12.4%
Q4 24
1.2%
28.6%
Q3 24
0.5%
17.5%
Q2 24
0.6%
8.2%
Q1 24
0.4%
48.2%
Cash Conversion
BCAL
BCAL
RXRX
RXRX
Q4 25
3.49×
Q3 25
1.02×
Q2 25
0.95×
Q1 25
0.41×
Q4 24
3.00×
Q3 24
Q2 24
1.63×
Q1 24
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons